Ibrutinib is a BTK inhibitor recently approved, February 2014, for the treatment of recurrent CLL. BTK plays an important role downstream the B cell receptor signaling (BCR) and is part of the Tec family of kinases. Signaling through BCR is essential to the AKT pathway and the NF-ÎB pathway (nuclear factor kappa light-chain enhancer of activated B cells). BCR signaling is also involved in B cells cell adhesion, migration and differentiation. Ibrutinib has been evaluated as frontline in elderly patients. It was found that the toxicities associated to this agent were mild. For example 68% of patients had grade 1 diarrhea and 45% grade 2 diarrhea.
New Therapeutic Advances in CLL (Ghayathri Jeyakumar)
Last date updated on July, 2014